NovaBiotics has been awarded £1.8 million in small business research innovation grant funding to advance its antifungal drug candidate, Novamycin. The drug is a first-in-class antifungal compound, intended for front-line treatment of medically unmet, tissue and bloodstream fungal infections caused by difficult to treat and drug resistant moulds and yeasts, including Aspergillus fumigates and Candida auris. The grant was made as part of a £10 million Small Business Research Initiative (SBRI) competition run by Innovate UK on behalf of DHSC, with the aim of supporting the implementation of the government’s five-year national antimicrobial resistance action plan. Source: Pharmatimes 19/2/2019